Navigation Links
Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Date:7/17/2008

y $1.4 billion, an increase of 16 percent. Double-digit growth across the portfolio was the result of robust sales of plasma-based therapies, products used for the treatment of hemophilia and immune disorders, biosurgery products and strong demand for the company's encephalitis vaccine.

Medication Delivery sales grew 12 percent in the quarter to approximately $1.2 billion, driven by strong international sales of IV therapy products and injectable drugs, as well as anesthesia products globally. Renal sales increased 8 percent to approximately $600 million as a result of an increase in peritoneal dialysis patients in many markets around the world.

The company continues to advance its product pipeline across its business portfolio. Investments in research and development in the quarter totaled $222 million, reflecting an increase of 25 percent over the prior-year period.

Six-Month Results

For the first six months of 2008, Baxter's net income totaled $973 million and increased 17 percent, with earnings per diluted share increasing 21 percent to $1.52. On an adjusted basis, Baxter's net income of $1.0 billion increased 16 percent from $880 million last year. Adjusted earnings per diluted share for the six-month period of $1.59 increased 20 percent, from $1.33 per diluted share in the prior year period.

Baxter's worldwide sales grew 10 percent in the first half of the year to $6.1 billion, an increase from $5.5 billion last year. Excluding the impact of foreign exchange, sales growth for the first six months of the year was 3 percent. Sales within the United States totaled $2.4 billion, an increase of 4 percent over the same period last year, and international sales grew 15 percent (or 3 percent excluding the impact of foreign exchange) to $3.6 billion.

Third Quarter and Full-Year 2008 Outlook

As a result of the strong performance in the first half of the year, Baxter is raising its financial outlook for full-year 2008. The
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Baxters Board of Directors Declares Quarterly Dividend
3. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
4. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
5. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
6. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
7. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
8. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
9. Baxter Declares Quarterly Dividend
10. Baxter Provides Update on Heparin Reactions
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
(Date:8/26/2014)... Diego, CA, and Bellingham, WA (PRWEB) August 26, ... and optical engineering, visions for next-generation wearable technology, ... 2015 among numerous highlights at this year’s brighter, ... the San Diego, California, Convention Center. More than ... last week attended conferences, courses, an exhibition, and ...
(Date:8/26/2014)... August 26, 2014 The 20 ambassadors ... ALS (YFALS) community issued the following statement on Facebook ... awareness and driving new funding specifically for ALS research: ... water and some ice would raise all this awareness ... our families, and on behalf of the entire ALS ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Competition for graphene 2
... Dec. 13, 2011  GenVec, Inc. (Nasdaq: GNVC ... create superior therapeutics and vaccines, today announced that Paul ... his plan to retire as President and Chief Executive ... a successor is named and the CEO transition is ...
... Tarsa Therapeutics today confirmed that it is planning ... Food and Drug Administration (FDA) in the second half ... calcitonin tablet for the treatment of postmenopausal osteoporosis. This follows ... the results from Tarsa,s Phase III ORACAL trial and ...
... - The Pharmabiotic Research Institute (PRI) brings ... probiotics research. It is a unique scientific and regulatory ... that, beyond their traditional food processing applications, probiotics can ... potential. This is why PRI uses the terminology "Pharmabiotics", ...
Cached Biology Technology:GenVec President and Chief Executive Officer Announces Retirement 2GenVec President and Chief Executive Officer Announces Retirement 3Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 2The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 4
(Date:8/27/2014)... into doubt the long-standing belief that a deficiency in ... plays a central role in depression. In the journal ... lacking the ability to make serotonin in their brains ... did not show depression-like symptoms. , Donald Kuhn ... Center and Wayne State University School of Medicine note ...
(Date:8/27/2014)... to be associated with outcomes after the repair ... the patient, mechanism of injury, nerve injured, injury ... technique, and repair materials. However, despite numerous studies ... injuries, there is no agreement regarding the independent ... relationship of the predictors has not been quantified. ...
(Date:8/27/2014)... North Carolina State University have found that century-old museum specimens ... common insect pest that can weaken and kill trees ... that scale insect populations increase on oak and maple trees ... pests may also increase with global warming," says Dr. Elsa ... of a paper on the work. , "More scale insects ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... human brain is not completed at birth. There is ... place in the human brain throughout life, probably for ... that brain structure is under considerable genetic influence [Peper ... into adulthood, involves changes in brain morphology that may ...
... , Mammography continues to be the method of ... because this technique is not as selective or specific ... results for every level of tissue density, alternatives are ... of near-infrared (NIR) light instead of X-rays, is a ...
... MANHATTAN, KAN. -- An award-winning Kansas State University chemistry ... recognizing him for work on microfluidic devices. Chris ... Masao Horiba Award for "Rapid Analysis of Individual T-Lymphocyte ... Wednesday, Oct. 17, during a special ceremony at Kyoto ...
Cached Biology News:Genetic contributions to human brain morphology and intelligence 2Genetic contributions to human brain morphology and intelligence 3Genetic contributions to human brain morphology and intelligence 4Genetic contributions to human brain morphology and intelligence 5Contrast agent trials in swine 2K-State chemistry professor to receive Masao Horiba award 2
... Mount is formulated for covering tissue sections and cell preparations ... end products. , ... Application: ... or AEC that require an aqueous mounting medium, or those ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Solution, pH 9 (x 10) This ... intended for heat-induced target retrieval prior to ... use on formalin-fixed, paraffin-embedded tissue sections mounted ... citrate buffer, pH 6, the use of ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: